Jazz Pharmaceuticals plc and Werewolf Therapeutics Inc. signed a licensing pact that could be worth more than $1.26 billion, assigning Jazz exclusive global development and commercialization rights to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback